Neurosense finalizing protocol for Phase 3 ALS trial of PrimeC
2024年12月19日 · In PARADIGM (NCT05357950), a completed Phase 2b study, PrimeC was tested against a placebo, both taken as two tablets by mouth twice daily for six months, in 68 adults diagnosed with ALS.Patients then had the option to enter an open-label extension where all received PrimeC for up to an additional 12 months. Consistent with earlier data, the 18-month readout showed that, compared with patients ...
Top 10 ALS news stories of 2024
2024年12月30日 · Read this story here. No. 8 – COYA 302 immune-modulating therapy shows promise in small early trial. Coya Therapeutics’ investigational therapy COYA 302 was found to slow ALS disease progression and lower levels of disease-related biomarkers in a small Phase 1 clinical trial. COYA 302 is a combination of an immune signaling molecule called interleukin-2 and a fusion protein called CTLA4-Ig ...
ALS News Today Home | ALS News Today
2025年1月17日 · ALS Nexus 2025 event aiming to make disease ‘livable’ for patients. The ALS Association this summer will host the second edition of its ALS Nexus, a conference bringing together researchers, healthcare professionals, advocates, patients, and caregivers in a quest to make amyotrophic lateral sclerosis (ALS) a more livable disease.
Largest ALS patient-based stem cell, biodata resource now open
2024年11月21日 · The largest of its kind, the repository contains biological and clinical data from nearly 1,000 ALS patients, as well as specialized nerve cells called induced pluripotent stem cells (iPSCs) derived from the patients that scientists can use as a resource for advancing ALS research and treatment.. Researchers can access the resources via the online, open-source Answer ALS Neuromine Data Portal ...
ALS respiratory data now available to researchers worldwide
2024年10月29日 · Developed under a collaboration between the nonprofit Target ALS and Zephyrx, the database features respiratory function data collected remotely and over time using Zephyrx’s at-home spirometry technology.As of August, 68 patients were using the technology to collect measures of lung function as their disease evolves.
Auttx gets ALS Network grant to develop new treatments for ALS
2024年11月5日 · Faster route to treatments for ALS. In ALS, certain proteins tend to form toxic clumps inside neurons and contribute to cell damage. A hallmark protein that’s dysfunctional in about 97% of all in ALS patients is TDP-43, which helps RNA inside the nucleus of cells to be appropriately processed.. When TDP-43 builds up outside the nucleus, it cannot perform its normal function.
Approval request starting in Canada for PrimeC in treating ALS
2024年10月14日 · Top-line data from the main trial showed that PrimeC treatment for six months tended to slow disease progression, as assessed by the ALS Functional Rating Scale-Revised (ALSFRS-R), and reduced lung function decline compared with a placebo.. These main trial differences failed to reach statistical significance, but data covering PARADIGM and its extension show that PrimeC could significantly ...
Initiative to use AI technologies to improve communication in ALS
2024年10月17日 · The Scott-Morgan Foundation (SMF), a nonprofit that’s pioneering assistive technology innovation, will lead a new initiative using artificial intelligence (AI) technologies to help people with diseases like amyotrophic lateral sclerosis (ALS) to better communicate and maintain their sense of identity.
Tiziana wins funding for small clinical trial in ALS of intranasal ...
2024年11月22日 · The upcoming trial intends to investigate the safety and effectiveness of two foralumab doses in 20 ALS patients. It builds on positive findings from multiple sclerosis (MS) patients, in whom the intranasal antibody therapy significantly decreased neuroinflammation and stabilized or reduced disability levels. Tiziana now wants to …
Medicare plans told to cover Qalsody for ALS tied to SOD1 …
2024年12月18日 · The directive comes after the ALS Association worked closely with the CMS, presenting evidence of widespread instances where coverage was wrongly denied to patients who met all the necessary criteria for the treatment. According to the group, the order is the first of its kind to be issued by the center. Qalsody, an injectable treatment marketed by Biogen, was conditionally approved by the U.S ...